---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061933"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:59:11.485293+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports Q3 FY2024 net loss $17.1M; sunRIZE Phase 3 enrolling, DME Phase 2 topline expected May 2024

## Summary
- Net loss $17.1M for Q3 FY2024 vs $15.7M YoY; cash and equivalents $81.6M (down from $118.4M in June 2023).
- sunRIZE Phase 3 for cHI (RZ358) enrolling; completion expected end-2024; topline data mid-2025.
- Completed in-vivo tox study in brown Norway rats at 40 mg/kg; no liver abnormalities; to submit to FDA summer 2024.
- DME Phase 2 (RZ402) completed dosing of 94 patients; topline results expected May 2024.
- FDA alignment for potential registrational study in tumor HI; 5 insulinoma patients treated under Expanded Access.

## SEC filing metadata
- accession: 0001104659-24-061933
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/0001104659-24-061933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/tm2414592d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061933
- JSON: https://secwatch.observer/filing/0001104659-24-061933.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061933.txt

## Key facts
- Earnings Releases
  Rezolute, Inc. reported the three months ended March 31, 2024 results: net income $17.1 million.
  - Period: the three months ended March 31, 2024
  - Net income: $17.1 million
  - Result: reported results
  source text: Net loss was $17.1 million for the third quarter of fiscal 2024 compared with a net loss of $15.7 million for the same period a year ago.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/0001104659-24-061933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.